Approximately 85% of patients with lung cancer present with NSCLC, with up to two-thirds harbouring actionable driver mutations, most commonly occurring in the epidermal growth factor receptor (EGFR) [3,4,5]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.